| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
14,310,000 |
| Market
Cap: |
9.45(M) |
| Last
Volume: |
26,960 |
Avg
Vol: |
26,885 |
| 52
Week Range: |
$0.5651 - $1.28 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Acer Therapeutics is a pharmaceutical company focused on the acquisition, development, and commercialization of therapies for rare and life-threatening diseases. Co.'s pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders and Maple Syrup Urine Disease; ACER-801 (osanetant) for the treatment of induced vasomotor symptoms; EDSIVO™ (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome in patients with a confirmed type III collagen mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, zika, dengue, ebola and COVID-19.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
1,229,508 |
| Total Buy Value |
$0 |
$0 |
$0 |
$1,500,000 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dunn John Michael |
Director |
– • – |
2023-11-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(27,380) |
0 |
|
- |
|
| Davis Jefferson E |
CHIEF BUSINESS OFFICER |
• – – |
2023-11-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(71,645) |
0 |
|
- |
|
| Joseph Donald |
See Remarks |
• – – |
2023-11-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,285) |
0 |
|
- |
|
| Aselage Steve |
Director |
– • – |
2023-11-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(483,741) |
0 |
|
- |
|
| Palmin Harry S |
CHIEF FINANCIAL OFFICER |
• – – |
2023-11-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(125,000) |
0 |
|
- |
|
| Schelling Chris |
PRESIDENT AND CEO |
• • • |
2023-11-17 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,712,529) |
0 |
|
- |
|
| Aselage Steve |
Director |
– • – |
2022-11-29 |
4 |
B |
$1.22 |
$500,000 |
D/D |
409,836 |
483,741 |
2.39 |
-16% |
|
| Schelling Chris |
President & CEO |
• • • |
2022-11-29 |
4 |
B |
$1.22 |
$1,000,000 |
D/D |
819,672 |
2,712,529 |
3.23 |
-16% |
|
| Aselage Steve |
Director |
– • – |
2021-12-10 |
4 |
B |
$2.04 |
$16,287 |
D/D |
7,984 |
73,905 |
2.39 |
6% |
|
| Aselage Steve |
Director |
– • – |
2021-12-09 |
4 |
B |
$2.15 |
$4,334 |
D/D |
2,016 |
65,921 |
2.31 |
2% |
|
| Davis Jefferson E |
Chief Business OfficerOfficer |
• – – |
2021-02-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
71,645 |
|
-15% |
|
| Dunn John Michael |
Director |
– • – |
2020-07-24 |
4 |
B |
$3.50 |
$74,998 |
D/D |
21,428 |
27,380 |
2.39 |
-22% |
|
| Aselage Steve |
Director |
– • – |
2020-07-24 |
4 |
B |
$3.50 |
$157,500 |
D/D |
45,000 |
63,905 |
2.39 |
-22% |
|
| Schelling Chris |
President & CEO |
• • • |
2020-07-24 |
4 |
B |
$3.50 |
$500,000 |
D/D |
142,857 |
1,892,857 |
3.23 |
-22% |
|
| Joseph Donald |
Chief Legal Officer and Secy |
• – – |
2020-07-24 |
4 |
B |
$3.50 |
$49,998 |
D/D |
14,285 |
14,285 |
2.74 |
-22% |
|
| Andrews William T. |
Chief Medical Officer |
• – – |
2020-03-02 |
4 |
D |
$3.28 |
$10,306 |
D/D |
(3,142) |
5,858 |
|
- |
|
| Aselage Steve |
Director |
– • – |
2019-07-03 |
4 |
B |
$3.72 |
$18,581 |
D/D |
5,000 |
18,905 |
2.39 |
- |
|
| Andrews William T. |
Chief Medical Officer |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
9,000 |
9,000 |
|
- |
|
| Leatt Gary |
10% Owner |
– – • |
2018-08-01 |
4 |
B |
$18.00 |
$4,950,000 |
I/I |
275,000 |
1,697,709 |
1.5 |
- |
|
| Aselage Steve |
Director |
– • – |
2017-12-14 |
4 |
B |
$12.00 |
$24,000 |
D/D |
2,000 |
13,905 |
2.39 |
- |
|
| Leatt Gary |
10% Owner |
– – • |
2017-12-12 |
4 |
B |
$12.00 |
$3,999,996 |
I/I |
333,333 |
1,422,709 |
1.5 |
- |
|
| Leatt Gary |
10% Owner |
– – • |
2017-09-19 |
4 |
A |
$0.00 |
$0 |
I/I |
2,063,976 |
1,172,709 |
|
- |
|
| Dunn John Michael |
|
• • – |
2017-09-19 |
4 |
A |
$0.00 |
$0 |
D/D |
5,952 |
5,952 |
|
- |
|
| Aselage Steve |
|
• • – |
2017-09-19 |
4 |
A |
$0.00 |
$0 |
D/D |
11,905 |
11,905 |
|
- |
|
| Palmin Harry S |
Chief Financial Officer |
• • – |
2017-09-19 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
125,000 |
|
- |
|
170 Records found
|
|
Page 1 of 7 |
|
|
